Physician profile
Sunil Hebbar
NPI 1619236593
$3,109.24
in general payments reported to CMS, 2019-2025
27 companies · $678 in 2025
The $678 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $740 · 2020: $331 · 2021: $395 · 2022: $169 · 2023: $325 · 2024: $471 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,474.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $682.18 | 2019-2025 | |
| Glaxosmithkline, LLC. | $624.05 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Gilead Sciences, INC. | $347.69 | 2019-2025 | |
| Amgen INC. | $204.42 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $173.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $140.58 | 2021-2023 | |
| Lilly USA, LLC | $91.52 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi Pasteur INC. | $85.46 | 2019-2025 | |
| Exact Sciences Corporation | $83.32 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $78.65 | 2021 | |
| Janssen Pharmaceuticals, INC | $78.39 | 2025 | Spravato |
| Merck Sharp & Dohme LLC | $72.73 | 2019-2025 | Capvaxive, Gardasil 9 |
| Allergan, INC. | $67.32 | 2019-2020 | |
| Ibsa Pharma INC. | $64.01 | 2020-2025 | Tirosint, Flector, Licart |
| Organon LLC | $59.26 | 2022-2023 | Nexplanon |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $39.28 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Eisai INC. | $32.45 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $29.60 | 2025 | Ultomiris |
| Phathom Pharmaceuticals, INC. | $22.23 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $21.17 | 2020 | |
| Tempus Ai, INC | $21.10 | 2024 | Xt Cdx |
| Sanofi-Aventis U.S. LLC | $20.99 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.00 | 2025 | Zoryve |
| Ironshore Pharmaceuticals INC. | $14.68 | 2019 | |
| Genentech USA, INC. | $14.21 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.89 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Hebbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.